Global Dry Powder Inhaler Device Market Research Report 2022

A dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus.

Due to the COVID-19 pandemic, the global Dry Powder Inhaler Device market size is estimated to be worth US$ 786.6 million in 2021 and is forecast to a readjusted size of US$ 1103.8 million by 2028 with a CAGR of 4.9% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Dry Powder Inhaler Device market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Dry Powder Inhaler Device landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, etc. are the key players in the global Dry Powder Inhaler Device market. Top 4 took up more than 30% of the global market.

From the view of region, USA have a larger consumption market share which account for about 35% of total share. Europe hold a market share of about 25%. In addition, Asia Pacific is also play important role in Global market.

Dry Powder Inhaler Device main application area is Asthma This sector hold a market share of over 80%. Then followed by the COPD.

According to the Segmentation of types, all the market of Dry Powder Inhaler Device can be divided as follows: Multi-dose, Single-dose.

This report focuses on Dry Powder Inhaler Device volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Dry Powder Inhaler Device market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Global Dry Powder Inhaler Device Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.


Segment by Type


Single Dose

Multi Dose


Segment by Application


Asthma

COPD

Others

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E


By Company


GlaxoSmithKline

AstraZeneca

Boehringer Ingelheim

Chiesi

Cipla

3M

Hovione

Mannkind

Mylan

Novartis

Schering/Merck

Teva

Vectura